Thuja Capital

Thuja Capital is a prominent Utrecht, Netherlands-based venture capital firm specializing in early-stage medical product innovations. Established with a clear mission to address unmet medical needs, the firm primarily targets companies developing novel medicines, advanced medical devices, and transformative digital health solutions. Their strategic focus is on groundbreaking technologies that have the potential to significantly impact patient care and healthcare systems globally, reflecting a deep commitment to advancing the healthcare sector.

The firm's investment strategy is highly specialized, concentrating on the critical early phases of company development. Thuja Capital typically deploys initial cheques ranging from approximately $540,000 (€500,000) to $3.24 million (€3 million). This initial capital is designed to support companies through crucial developmental milestones, including preclinical studies, clinical trials, and regulatory approvals. Beyond the initial investment, Thuja Capital demonstrates a strong commitment to its portfolio companies, with the capacity to invest up to $10.8 million (€10 million) per company over multiple funding rounds, providing sustained support as ventures mature and scale.

Thuja Capital manages a series of dedicated healthcare funds, underscoring its deep expertise and long-term commitment to the sector. Their most recent vehicles include Thuja Capital Healthcare Fund III, launched in 2021 with a target size of €100 million, and Thuja Capital Healthcare Fund IV, launched in 2023 with an ambitious target of €125 million. These substantial funds enable Thuja Capital to maintain a robust investment pipeline and provide significant capital to promising ventures. The firm's hands-on approach involves not just financial backing but also strategic guidance, leveraging their extensive network and industry knowledge to help portfolio companies navigate the complex landscape of healthcare innovation.